 Shares of Reviva Pharmaceuticals Holdings, Inc. NASDAQ: RVPH more than doubled in value Monday after the clinical-stage biopharmaceutical company reported encouraging phase 2 clinical trial results for its lead drug candidate. Positive trial results: Possibility for superior safety label Revivas lead drug candidate, RP5063 brilaroxazine for Acute Schizophrenia, met its primary endpoint of achieving a ... The post Heres why Reviva Pharmaceuticals soared more than 100 on Monday appeared first on Invezz. 